预约演示

更新于：2025-01-23

CombiVICHvac(State Research Center of Virology and Biotechnology VECTOR)

更新于：2025-01-23

概要

概要

基本信息

药物类型

DNA疫苗、治疗性疫苗

别名

VLP-TBI-pcDNA-TCI

靶点-

作用机制

免疫刺激剂

治疗领域

免疫系统疾病感染泌尿生殖系统疾病

在研适应症

HIV感染

非在研适应症-

原研机构

State Research Center of Virology and Biotechnology VECTOR

在研机构

State Research Center of Virology and Biotechnology VECTOR

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 79423

Sequence Code 1120173647

Sequence Code 107187

Sequence Code 36380

Sequence Code 1120173648

关联

100 项与 CombiVICHvac(State Research Center of Virology and Biotechnology VECTOR) 相关的临床结果

登录后查看更多信息

100 项与 CombiVICHvac(State Research Center of Virology and Biotechnology VECTOR) 相关的转化医学

登录后查看更多信息

100 项与 CombiVICHvac(State Research Center of Virology and Biotechnology VECTOR) 相关的专利（医药）

登录后查看更多信息

项与 CombiVICHvac(State Research Center of Virology and Biotechnology VECTOR) 相关的文献（医药）

2008-02-01·Molecular Immunology3区 · 医学

A synergistic effect of a combined bivalent DNA–protein anti-HIV-1 vaccine containing multiple T- and B-cell epitopes of HIV-1 proteins

3区 · 医学

Article

作者: Leonid R. Lebedev ; Roman V. Uzhachenko ; Sergei I. Bazhan ; Alexander A. Ilyichev ; Larisa I. Karpenko ; Alexey M. Eroshkin ; Pavel A. Belavin

Immunogenic properties of the combined vaccine CombiHIVvac, comprising polyepitope HIV-1 immunogens, one being the artificial polyepitope protein TBI, containing the T- and B-cell epitopes from Env and Gag proteins, and the DNA vaccine construct pcDNA-TCI coding for the artificial protein TCI, carrying over 80 T-cell epitopes (both CD4+ CTL and CD8+ Th) from Env, Gag, Pol, and Nef proteins, are studied in this work. The data reported demonstrate clearly that a combination of two B- and T-cell immunogens (TBI and TCI) in one construct results in a synergistic increase in the antibody response to both TBI protein and the proteins from HIV-1 lysate. The level of antibodies induced by immunization with the constructs containing either immunogen alone (TBI protein or the plasmid pcDNA-TCI) was significantly lower as compared to that induced by the combined vaccine. The analysis performed suggests that the presence of CD4+ T-helper epitopes, which can be presented by MHC class II, in the protein TCI may be the main reason underlying the increased synthesis of antibodies to TBI protein due to a CD4-mediated stimulation of B-cell proliferation and differentiation.

2007-05-01·Vaccine3区 · 医学

Combined virus-like particle-based polyepitope DNA/protein HIV-1 vaccine

3区 · 医学

Article

作者: Sergei V. Seregin ; Sergei I. Bazhan ; Leonid R. Lebedev ; Roman V. Uzhachenko ; Elena D. Danilenko ; Alexander A. Ilyichev ; Olga A. Plyasunova ; Nadezhda K. Danilyuk ; Larisa I. Karpenko ; Valentina I. Masycheva ; Alexey M. Eroshkin ; Nadezhda A. Nekrasova ; Pavel A. Belavin ; Boris N. Zaitsev

We have previously described designing of polyepitope immunogens TBI and TCI, to stimulate the humoral and cellular immune responses to HIV-1. Here, immunogens TBI and TCI were used to create new vaccine construct named CombiHIVvac (Combined HIV-1 vaccine). CombiHIVvac is a virus-like particles (VLP) containing the DNA vaccine pcDNA-TCI as a core encapsulated within a spermidine-polyglucin-TBI conjugate. The immunogenic and toxic properties of the candidate vaccine CombiHIVvac have been studied. CombiHIVvac induces a strong humoral and CTL responses in mice; the antibodies are highly specific and are able to neutralize HIV-1 in vitro. Preclinical study demonstrated that CombiHIVvac does not cause long-term changes in physiological, biochemical and morphological parameters in immunized animals and thus can be recommended for clinical trials.

2004-04-01·Vaccine3区 · 医学

Comparative analysis using a mouse model of the immunogenicity of artificial VLP and attenuated Salmonella strain carrying a DNA-vaccine encoding HIV-1 polyepitope CTL-immunogen

3区 · 医学

Article

作者: Irina N Babkina ; Sergei V Seregin ; Leonid R Lebedev ; Boris N Zaitsev ; Pavel A Belavin ; George M Ignatyev ; Alexander P Agafonov ; Larisa I Karpenko ; Alexander A Ilyichev ; Nadezhda K Danilyuk ; Sergei I Bazhan ; Nadezhda A Nekrasova

Two systems have been examined for delivery of DNA-vaccine encoding a HIV-1 polyepitope CTL-immunogen (TCI). One is intended for i.m. injection and is in the form of an artificial virus like particle containing eukaryotic expression plasmid pcDNA-TCI encapsulated within a spermidine-polyglucin conjugate. The other is intended for mucosal immunization and is based on attenuated Salmonella typhimurium strain 7207, which can deliver pcDNA-TCI directly into professional antigen-presenting cells (APC). After immunization, the artificial VLP and recombinant Salmonella induced an enhanced HIV specific serum antibody, proliferative and CTL responses compared to those induced by naked pcDNA-TCI. The most significant responses were produced when pcDNA-TCI was delivered by Salmonella.

100 项与 CombiVICHvac(State Research Center of Virology and Biotechnology VECTOR) 相关的药物交易

登录后查看更多信息